Abstract: The present invention provides pharmaceutical compositions which include (?)-pseudoephedrine and a pharmaceutically acceptable carrier, wherein the (?)-pseudoephedrine is substantially-free of (+)-pseudoephedrine. In another embodiment, the present invention provides methods of relieving nasal and bronchial congestion and of inducing pupil dilation which include administering a pharmaceutically effective amount of (?)-pseudoephedrine to a mammal. The (?)-pseudoephedrine used in the present methods is substantially free of (+)-pseudoephedrine and also substantially free of side effects caused by administration of (+)-pseudoephedrine.

Abstract: Methods and compositions used for lowering intraocular pressure. More particularly, the methods and compositions for lowering intraocular pressure pertain to the use of at least a phenanthroline derivative in an ophthalmic delivery solution.

Abstract: A pharmaceutical composition, containing a therapeutically effective amount of an endothelin (“ET”) antagonists and/or an endothelin-converting enzyme (“ECE”) inhibitors and a pharmaceutically acceptable carrier. The pharmaceutical composition is useful for treating normal-tension and primary open-angle glaucoma and prevents optic nerve damage and retinal ganglion cell death associated with these ocular diseases.

Abstract: The present invention provides pharmaceutical compositions which include (−)-pseudoephedrine and a pharmaceutically acceptable carrier, wherein the (−)-pseudoephedrine is substantially-free of (+)-pseudoephedrine. In another embodiment, the present invention provides methods of relieving nasal and bronchial congestion and of inducing pupil dilation which include administering a pharmaceutically effective amount of (−)-pseudoephedrine to a mammal. The (−)-pseudoephedrine used in the present methods is substantially free of (+)-pseudoephedrine and also substantially free of side effects caused by administration of (+)-pseudoephedrine.

Abstract: The present invention provides pharmaceutical compositions which include (−)-pseudoephedrine and a pharmaceutically acceptable carrier, wherein the (−)-pseudoephedrine is substantially-free of (+)-pseudoephedrine. In another embodiment, the present invention provides methods of relieving nasal and bronchial congestion and of inducing pupil dilation which include administering a pharmaceutically effective amount of (−)-pseudoephedrine to a mammal. The (−)-pseudoephedrine used in the present methods is substantially free of (+)-pseudoephedrine and also substantially free of side effects caused by administration of (+)-pseudoephedrine.

Abstract: Compounds of formula: ##STR1## where X is --CH.sub.2 --, --CH(CH.sub.3)--, --CHR.sub.3 --CH.sub.2 -- or --CR.sub.3 .dbd.CH-- and R.sub.1, R.sub.2 and R.sub.3, which can be the same or different, are each H or CH.sub.3 or a stereoisomer or pharmaceutically acceptable salt thereof, and pharmaceutical compositions containing them, are useful for lowering intraocular pressure in a mammal, e.g. in the treatment of glaucoma.